{"title":"Milestones In Drug Therapy","description":"\u003cp\u003eExplore the 'Milestones in Drug Therapy' collection, charting the evolution of pharmaceutical treatments and their profound impact on healthcare. A must-read for medical professionals and anyone fascinated by the history of medicine.\u003c\/p\u003e","products":[{"product_id":"treatment-of-psoriasis-book-jeffrey-m-weinberg-9783764377229","title":"Treatment of Psoriasis","description":"Psoriasis is an inherited skin disease that has been diagnosed in 4.5 million adults in the United States. About 10 percent to 30 percent of people with psoriasis also develop psoriatic arthritis, which causes pain, stiffness and swelling in and around the joints.       The book reviews the clinical manifestations of these two entities. The main focus is on the evolving paradigm of therapy. Topical and ultraviolet therapy are discussed first, followed by traditional systemic therapy. A major focus is on biologic therapies. New agents in development are also reviewed. The book concludes with an evaluation of the quality of life impact of this disease.      This volume provides an in-depth overview of the current state of psoriasis and its management. It is of interest to clinicians, researchers, and even patients who wish to learn more. It is also of interest to those in the pharmaceutical industry, and those in finance who cover the pharmaceutical field.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ GARDNERS","offer_id":49736432779537,"sku":"NGR9783764377229","price":0.0,"currency_code":"GBP","in_stock":false},{"title":"GB \/ NEW \/ INGRAM","offer_id":52655733113105,"sku":"NLS9783764377229","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/3764377224.jpg?v=1750773818"},{"product_id":"sildenafil-book-udo-dunzendorfer-9783764362553","title":"Sildenafil","description":"This drug is a landmark discovery, which consequently has become the definitive therapy for the treatment of erectile dysfunction (ED). Following the major breakthrough in the field of nitric oxide (NO)-physiology and pharmacology leading to sildenafil being marketed, the most current information is presented in this reference book, including ongoing research from several disparate groups about NO as endothelium-derived relaxing factor (EDRF) and also as a neurotransmitter for nerves innervating erectile tissue in mammals.   The development of sildenafil as an oral phosphodiesterase-5 (PDE5) inhibitor drug for the treatment of ED resulted in one of the first products, which made its way successfully from basic NO research to routine clinical therapy.   This volume addresses all fields of sildenafil application in both men and women. In a highly competitive research environment with a critical medical need for drug improvements the reader will learn more about clinical resistance to sildenafil treatment and the modalities to overcome the failure rates.    The individual chapters cover clinical use, pharmacokinetics, pharmacodynamics, biochemistry, and cultural aspects. They are written by leading experts in their respective fields. Therefore, readers – whether professionals in the pharmaceutical industry, physicians treating ED, biochemists, chemists or pharmacologists – will find a detailed and up-to-date knowledge base about current research activities and an excellent overview for further research on this compound class and its cultural impact.","brand":"WoB","offers":[{"title":"- \/ - \/ -","offer_id":50514509725969,"sku":"","price":0.0,"currency_code":"GBP","in_stock":true},{"title":"GB \/ VERY_GOOD \/ INTERNAL","offer_id":50514510381329,"sku":"GOR011637817","price":0.0,"currency_code":"GBP","in_stock":false},{"title":"GB \/ NEW \/ INGRAM","offer_id":52335371944209,"sku":"NLS9783764362553","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/3764362553.jpg?v=1751383416"},{"product_id":"glucocorticoids-book-nj-goulding-9783034895286","title":"Glucocorticoids","description":"Following 50 years of glucocorticoid use in a clinical setting, an  international body of expert scientists and physicians presents the most  expansive survey of glucocorticoid pharmacology to date. This work  traces the history of glucocorticoid biology from the seminal  description of glucocorticoid insufficiency by Thomas Addison in the  mid-19th century, up to current advances in elucidating the molecular  basis of glucocorticoid action. Important discoveries are presented, as  well as milestones in drug development, a survey of current clinical  practice, and prospects for novel glucocorticoid-based therapeutics.  Scientists and clinicians will appreciate the scope of this work, which  is of special interest to workers in the fields of endocrinology,  inflammation and autoimmune disease.","brand":"WoB","offers":[{"title":"- \/ - \/ -","offer_id":51061591965969,"sku":"","price":0.0,"currency_code":"GBP","in_stock":true},{"title":"US \/ NEW \/ INGRAM","offer_id":51061595144465,"sku":"NIN9783034895286","price":0.0,"currency_code":"GBP","in_stock":false},{"title":"GB \/ NEW \/ INGRAM","offer_id":52140907561233,"sku":"NLS9783034895286","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/3034895283.jpg?v=1753786622"},{"product_id":"methotrexate-book-bruce-n-cronstein-9783034895736","title":"Methotrexate","description":"Although surprising, it seems fitting that a drug developed at the dawn of the era of rational drug design and therapeutics, methotrexate, should remain in common use for the therapy of so many different kinds of illnesses. Moreover, methotrexate has completely revolutionized the way in which medicine is practiced in a number of speciality areas. First developed to treat malignancies, methotrexate is now commonly used to treat gynecological problems, inflammatory arthritis, skin disease and probably other ailments as well. This work is designed to give a broad overview of the history of methotrexate's development, its prior use and its current therapeutic uses. As discussed in Chapter I, aminopterin and methotrexate were designed to inhibit mammalian folate metabolism but the concept of folic acid antag­ onism was soon applied to the development of antibacterial and anti­ parasitic agents. Trimethoprim and sulfa drugs were among the first antibiotics developed and they also remain quite useful today for the treat­ ment of a variety of infections.","brand":"WoB","offers":[{"title":"- \/ - \/ -","offer_id":51064850645265,"sku":"","price":0.0,"currency_code":"GBP","in_stock":true},{"title":"US \/ NEW \/ INGRAM","offer_id":51064853037329,"sku":"NIN9783034895736","price":0.0,"currency_code":"GBP","in_stock":false},{"title":"GB \/ NEW \/ INGRAM","offer_id":52428030837009,"sku":"NLS9783034895736","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/3034895739.jpg?v=1754195414"},{"product_id":"tamoxifen-book-philipp-y-maximov-9783034806633","title":"Tamoxifen","description":"Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years.  This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen’s pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.","brand":"WoB","offers":[{"title":"US \/ NEW \/ INGRAM","offer_id":51064885838097,"sku":"NIN9783034806633","price":0.0,"currency_code":"GBP","in_stock":false},{"title":"GB \/ NEW \/ INGRAM","offer_id":52662395797777,"sku":"NLS9783034806633","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/3034806639.jpg?v=1751221147"},{"product_id":"pegylated-protein-drugs-basic-science-and-clinical-applications-book-francesco-m-veronese-9783764386788","title":"PEGylated Protein Drugs: Basic Science and Clinical Applications","description":"PEGylation technology and key applications are introduced by this topical volume. Basic physical and chemical properties of PEG as basis for altering\/improving in vivo behaviour of PEG-conjugates such as increased stability, improved PK\/PD, and decreased immunogenicity, are discussed. Furthermore, chemical and enzymatic strategies for the coupling and the conjugate characterization are reported. Following chapters describe approved and marketed PEG-proteins and PEG-oligonucleotides as well as conjugates in various stages of clinical development.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52124098232593,"sku":"NLS9783764386788","price":0.0,"currency_code":"GBP","in_stock":true},{"title":"US \/ NEW \/ INGRAM","offer_id":52762245234961,"sku":"NIN9783764386788","price":0.0,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764386788.jpg?v=1757455441"},{"product_id":"fluoroquinolone-antibiotics-book-allan-r-ronald-9783764365912","title":"Fluoroquinolone Antibiotics","description":"Since the introduction of ciprofloxacin in 1987, fluoroquinolones have expanded far beyond their early role in the treatment of urinary tract infections. Clinical applications beyond genitourinary tract infections include upper and lower respiratory infections, gastrointestinal infections, gynecologic infec- tions, sexually transmitted diseases, and some skin and soft tissue infections. Their ease of administration, favorable pharmacokinetic properties, excellent tolerability, and efficacy give them enormous potential for use and misuse alike. Quinolones have few common adverse effects, most notably nausea, headache and dizziness. Less frequent but more serious adverse events include prolongation of the corrected QT interval, phototoxicity, liver enzyme abnor- malities, arthropathy, and cartilage and tendon abnormalities. While possess- ing many of the favorable properties of intravenous agents, most fluoro- quinolones offer the convenience of oral administration, thus contributing to decreased health-care costs through increased outpatient therapy and short- ened hospital stays. With the recent introduction of agents such as gatifloxacin and moxifloxacin, the traditional Gram-negative coverage of fluoroquinolones has been expanded to include Gram-positive organisms, most importantly Streptococcus pneumoniae.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52128061325585,"sku":"NLS9783764365912","price":0.0,"currency_code":"GBP","in_stock":true},{"title":"US \/ NEW \/ INGRAM","offer_id":52762254639377,"sku":"NIN9783764365912","price":0.0,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764365912.jpg?v=1757489401"},{"product_id":"macrolide-antibiotics-book-w-schnfeld-9783034894388","title":"Macrolide Antibiotics","description":"There are only very few chemical classes of antibiotics in medical use, and these have originated over a span of more than 60 years of research. Almost half a century ago, the first member of the macrolides, erythromycin, was introduced as a treatment option for bacterial infections. Erythromycin is a very complex fermentation product obtained from the soil bacterium Saccharopolyspora ery- thraea (originally named Streptomyces erythreus). The success of erythromycin, based on its efficacy and tolerability, stimulated researchers throughout the world to undertake intense efforts to understand the biology and chemistry of macrolides and to use this experience to improve the properties of this compound class. The second generation of macrolides, based on chemical modifications of erythromy- cin, is currently being in broad use, especially for treatment of respiratory tract infections. We presently foresee the introduction of a new generation of macro- lides, i. e. the ketolides, which have the potential to overcome rising resistance problems. This monograph is intended to give the interested reader an overview on macrolide experience, covering important areas from basic research to clinical use. Starting from a historic overview, the essential basic parameters - efficacy, pharmacokinetics, pharmacodynamics, and pharmacology - are highlighted in order to introduce the reader to the rationale for clinical use of macrolides. The following group of chapters cover the complex chemistry of the macro- lactone structures, giving historic background, basic structure-activity relation- ships of various derivatization strategies, and perspectives for future discovery of new semisynthetic macrolide antibiotics.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52128128270609,"sku":"NLS9783034894388","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783034894388.jpg?v=1757489587"},{"product_id":"anxiolytics-book-mike-briley-9783764360320","title":"Anxiolytics","description":"For over thirty years the benzodiazepines monopolised not only the anxiolytic market but also clinical and animal research in anxiety. Indeed many animal tests developed since the 1960s have been optimised for the benzodiazepines and some programmes have even screened candidates as potential anxiolytics on their benzodiazepine-like side-effects rather than their anxiolytic activity. With the realisation of the drawbacks of the benzodiazepines, namely their potential for tolerance and dependency, there has been a renewed interest in alternative anxiolytics both from existing drugs such as the tricyclic and monoamine oxidase antidepressants and from newer agents such as buspirone. In addition anxiety is no longer considered to be a unique entity but rather an umbrella term for a series of specific anxiety disorders such as panic disorder without or with agoraphobia, generalised anxiety disorder (GAD), specific phobias, social phobias and post-traumatic stress disorder (PTSD). These new clinical categories have opened another dimension in the therapy of anxiety requiring the optimisation of treatments for different syndromes. This book is a critical review of today's anxiolytics and those that may become the anxiolytics of tomorrow. What is clear is that currently there are few clinically satisfactory alternatives to the benzodiazepines for the treatment of acute anxiety. For chronic anxiety, it is generally agreed that benzodi- azepines are not the treatment of first choice. The tricyclic and monoamine oxidase antidepressants, the serotonin reuptake inhibitors and buspirone offer better solutions for chronic anxiety but they are still far from being ideal.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52129274233105,"sku":"NLS9783764360320","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764360320.jpg?v=1757495765"},{"product_id":"macrolide-antibiotics-book-w-schnfeld-9783764361860","title":"Macrolide Antibiotics","description":"There are only very few chemical classes of antibiotics in medical use, and these have originated over a span of more than 60 years of research. Almost half a century ago, the first member of the macrolides, erythromycin, was introduced as a treatment option for bacterial infections. Erythromycin is a very complex fermentation product obtained from the soil bacterium Saccharopolyspora ery- thraea (originally named Streptomyces erythreus). The success of erythromycin, based on its efficacy and tolerability, stimulated researchers throughout the world to undertake intense efforts to understand the biology and chemistry of macrolides and to use this experience to improve the properties of this compound class. The second generation of macrolides, based on chemical modifications of erythromy- cin, is currently being in broad use, especially for treatment of respiratory tract infections. We presently foresee the introduction of a new generation of macro- lides, i. e. the ketolides, which have the potential to overcome rising resistance problems. This monograph is intended to give the interested reader an overview on macrolide experience, covering important areas from basic research to clinical use. Starting from a historic overview, the essential basic parameters - efficacy, pharmacokinetics, pharmacodynamics, and pharmacology - are highlighted in order to introduce the reader to the rationale for clinical use of macrolides. The following group of chapters cover the complex chemistry of the macro- lactone structures, giving historic background, basic structure-activity relation- ships of various derivatization strategies, and perspectives for future discovery of new semisynthetic macrolide antibiotics.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52129526219025,"sku":"NLS9783764361860","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764361860.jpg?v=1757496606"},{"product_id":"combination-therapy-of-aids-book-erik-de-clercq-9783764366001","title":"Combination Therapy of AIDS","description":"HIV infection has been a greater challenge to current medicine than any other viral disease ofmodem times. HIV leads to a persistent infection and the virus has an immense genetic flexibility under selective pressure. During its replica- tive cycle in patients, HIV accumulates mutations at such a high rate that the selective pressure inflicted on the immune system, or generated by antiviral drugs rapidly triggers the appearance of escape mutants. Currently available drugs, when used singly, are not capable of suppressing virus replication in patients to such a level that the generation of mutations, from which a variant resistant to immune attack or antiviral drugs can be selected, is prevented. This is the main reason why combination therapy, usually of three drugs, has become the standard procedure for the treatment ofAIDS. It is obvious that virus eradication will not readily be achievable, so that drugs have to be taken for a prolonged time or even lifelong so as to keep the viral load as low as possible. Whether the currently used drug combinations will be able to control virus replication in a particular patient for such a pro- longed period of time depends on many factors, most of which are addressed in the different chapters of this book. The aim of antiviral drug combination therapy for AIDS is ultimately to restore full function of the immune system.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52130010202385,"sku":"NLS9783764366001","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764366001.jpg?v=1757500972"},{"product_id":"drugs-affecting-growth-of-tumours-book-herbert-m-pinedo-9783764321963","title":"Drugs Affecting Growth of Tumours","description":"During recent years the field of effective anticancer agents has substantially increased. The use of chemotherapy has been accepted as a standard therapy for an expanding number of tumour types and stages, while many new agents are being investigated when standard therapy is lacking or failing. Apart from new targets for anticancer agents, attention is also focused on improving efficacy and tolerability of existing compounds.   This topical volume provides an up-to-date overview of clinically relevant data on anticancer agents, and is not only intended for those working as a medical doctor with cancer patients, but also for medical researchers and students. The different classes of anticancer drugs are described by international authorities on the various topics.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52141508002065,"sku":"NLS9783764321963","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764321963.jpg?v=1757577282"},{"product_id":"cognitive-enhancing-drugs-book-jerry-j-buccafusco-9783034896030","title":"Cognitive Enhancing Drugs","description":"During the past decade research into the pharmacology of cognition, particularly regarding learning and memory, has supported the concept that many potential neural targets exist for the development of cognitive-enhancing drugs.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52141528908049,"sku":"NLS9783034896030","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783034896030.jpg?v=1757577326"},{"product_id":"recombinant-protein-drugs-book-p-buckel-9783034895279","title":"Recombinant Protein Drugs","description":"Recombinant protein drugs are intimately associated with the impressive  success story of the Biotech Industry during the past thirty years, some  of them belonging to the most successful pharmaceutical products. More  than thirty different proteins are available for a variety of clinical  applications, over 300 proteins are presently being evaluated in  clinical trials.  In this new volume of the MDT series, historical, technical and clinical  aspects of recombinant protein drug discovery and development are  presented, covering past, present and future highlights. Leading  scientists and co-founders of early Biotech companies describe technical  breakthroughs and the fascinating story of pioneering discoveries, as  well as the long way of translating them into products and business.  Therefore, this book represents an exciting documentation of the  beginning of a new era in the pharmaceutical industry. In addition,  scientists from basic research, clinic and industry actively involved in  new developments discuss...","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52141734887697,"sku":"NLS9783034895279","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783034895279.jpg?v=1757578019"},{"product_id":"combination-therapy-of-aids-book-erik-de-clercq-9783034896047","title":"Combination Therapy of AIDS","description":"HIV infection has been a greater challenge to current medicine than any other viral disease ofmodem times. HIV leads to a persistent infection and the virus has an immense genetic flexibility under selective pressure. During its replica- tive cycle in patients, HIV accumulates mutations at such a high rate that the selective pressure inflicted on the immune system, or generated by antiviral drugs rapidly triggers the appearance of escape mutants. Currently available drugs, when used singly, are not capable of suppressing virus replication in patients to such a level that the generation of mutations, from which a variant resistant to immune attack or antiviral drugs can be selected, is prevented. This is the main reason why combination therapy, usually of three drugs, has become the standard procedure for the treatment ofAIDS. It is obvious that virus eradication will not readily be achievable, so that drugs have to be taken for a prolonged time or even lifelong so as to keep the viral load as low as possible. Whether the currently used drug combinations will be able to control virus replication in a particular patient for such a pro- longed period of time depends on many factors, most of which are addressed in the different chapters of this book. The aim of antiviral drug combination therapy for AIDS is ultimately to restore full function of the immune system.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52141813727505,"sku":"NLS9783034896047","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783034896047.jpg?v=1757578306"},{"product_id":"atypical-antipsychotics-book-bart-a-ellenbroek-9783764359485","title":"Atypical Antipsychotics","description":"The introduction of chlorpromazine in 1953, and haloperidol in 1958, into clinical practice dramatically altered the therapy of schizophrenic patients. Although representing by no means a cure for this severe psychiatric ill­ ness, it allowed, for the first time, to adequately control the severe hallu­ cinations and delusional beliefs which prevent these patients from leading a more or less independent life. Indeed these antipsychotics (and the many congeners that were to follow) significantly reduced the number ofchronic schizophrenic inpatients in psychiatric clinics all over the world. However soon after their introduction it became clear that, like all other available drugs, antipsychotics were by no means miracle drugs. In fact, two major problems appeared. First, the antipsychotics had very little effect on the so-called negative or defect symptoms, like social isolation, apathy and anhedonia, and secondly virtually all antipsychotics produced a number of side-effects, of which the neurological (often called extra­ pyramidal) side-effects were the most troublesome. Especially the tardive dyskinesia, which occurred in about 15 to 20% of the patients after pro­ longed treatment, represented a major problem in the treatment of schizo­ phrenic patients.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52141863895313,"sku":"NLS9783764359485","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764359485.jpg?v=1757578434"},{"product_id":"next-generation-antibody-drug-conjugates-adcs-and-immunotoxins-book-ulf-grawunder-9783319468754","title":"Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins","description":"This book describes the newest developments in antibody drug conjugates and immunotoxins, paving their way to clinical application. Lessons learned from the current state of the art are used to further improve our understanding of their mechanisms of action and off target activities.     The book introduces scientists to all of the prerequisites that must be properly addressed, including identification of the right target, specific traits of target binding antibodies, proper selection of the toxic payload, internalization induced by binding, and next generation conjugation and linker technologies. These knowledge-based, revolutionary new drug principles will form the cornerstone of the future standard of care and will lead to major advances in application, as well as improved quality of life and patient survival rates. This book will be of interest to biotech companies and researchers working in the fields of immunology, pharmacology, and oncology.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52146206179601,"sku":"NLS9783319468754","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783319468754.jpg?v=1757596938"},{"product_id":"erythropoietins-erythropoietic-factors-and-erythropoiesis-book-steven-g-elliott-9783764386948","title":"Erythropoietins, Erythropoietic Factors, and Erythropoiesis","description":"Research on, and interest in, red blood cell formation spans several centuries and was thought to have peaked in the 1980s with the cloning of the eryth- poietin (EPO) gene. In the years subsequent to the cloning of EPO and its expression as a recombinant protein, much was written about EPO. Although much has been learned and published, new, exciting data are becoming ava- able on almost a daily basis. Erythropoietins and Erythropoiesis: Molecular, Cellular, Preclinical, and Clinical Biology compiles both pertinent historical and very recent research on this molecule and its clinical utility. The book is divided into two sections: Background and Basic Science and Clinical Uses of Recombinant Erythropoietins. To begin, Israels and Israels describe the biology of red cells, the hierarchy of erythropoietic progenitor cells, their development to mature cells, and the effects of endogenous EPO on their development. Foote summarizes the historical interest in, and search for, an erythropoietic factor. Once EPO was identified, cloned, and expressed, the path was set for the study of other aspects of EPO biology both within e- thropoiesis and other cellular systems.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52148434665745,"sku":"NLS9783764386948","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764386948.jpg?v=1757603573"},{"product_id":"tamoxifen-book-philipp-y-maximov-9783034807838","title":"Tamoxifen","description":"Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a failed morning after contraceptive to become the gold standard for the treatment of breast cancer.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52152320885009,"sku":"NLS9783034807838","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783034807838.jpg?v=1757616268"},{"product_id":"hepatitis-prevention-and-treatment-book-joseph-m-colacino-9783764359560","title":"Hepatitis Prevention and Treatment","description":"Chronic viral hepatitis has emerged as one of the most common causes of disease and death worldwide. Because of their unique modes of replication and intimate association with the host immune system, hepatitis B virus (HBV) and hepatitis C virus (HCV) pose challenging problems to scientists in basic and applied research as well as to clinicians engaged in disease management. Although approved antiviral therapy is available for chronic HBV, the emergence of viral resistance provides a rationale for the development of novel chemotherapeutic agents. The lack of a robust cell culture system for HCV replication and a readily accessible small-animal model of HCV infection have hampered the development of antiviral agents for HCV. Neverthe-less, new antiviral agents targeting HCV are now in preclinical and clinical development.   This monograph, providing an up-to-date overview of the field of Hepatitis Prevention and Treatment, includes contributions from internationally recognized experts in the field of viral hepatitis, and covers the current state of knowledge and practice regarding the molecular biology, immunology, biochemistry, pharmacology and clinical aspects of chronic HBV and HCV infection. The volume includes salient topics such as: the history and epidemiology of HBV and HCV; recent insights into the molecular mechanisms of viral replication; the host immune response to infection and a discussion of the use (HBV) or potential development (HCV) of vaccines; the current standard of care for chronically-infected patients; and emerging therapies and issues associated with current antiviral treatments. The latest information to researchers and clinicians actively engaged in viral hepatitis research is provided, but also sufficient background and discussion of the literature to benefit the newcomer to the field.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52335522644241,"sku":"NLS9783764359560","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764359560.jpg?v=1758160287"},{"product_id":"calcium-channel-blockers-book-thophile-godfraind-9783764364359","title":"Calcium Channel Blockers","description":"The main effect of calcium channel blockers is the blockade of calcium entry into cells through voltage operated calcium channels. This volume gives a comprehensive overview of the different classes of CCBs and their various effects. It covers historical development, pharmacology, clinical aspects, and perspectives.","brand":"WoB","offers":[{"title":"- \/ - \/ INTERNAL","offer_id":52335735996689,"sku":null,"price":0.0,"currency_code":"GBP","in_stock":true},{"title":"GB \/ NEW \/ INGRAM","offer_id":52335736619281,"sku":"NLS9783764364359","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764364359.jpg?v=1758160987"},{"product_id":"cognitive-enhancing-drugs-book-jerry-j-buccafusco-9783764369828","title":"Cognitive Enhancing Drugs","description":"During the past decade research into the pharmacology of cognition, particularly regarding learning and memory, has supported the concept that many potential neural targets exist for the development of cognitive-enhancing drugs.","brand":"WoB","offers":[{"title":"- \/ - \/ INTERNAL","offer_id":52336192094481,"sku":null,"price":0.0,"currency_code":"GBP","in_stock":true},{"title":"GB \/ NEW \/ INGRAM","offer_id":52336192553233,"sku":"NLS9783764369828","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764369828.jpg?v=1758162534"},{"product_id":"cox-2-inhibitors-book-michel-pairet-9783764369019","title":"COX-2 Inhibitors","description":"COX-2 inhibitors are important drugs with analgesic and anti-inflammatory effects. The discovery of COX-2, the evolution of drug development in this field and the implications of these developments in patient therapy are topics of this volume. This book presents both pre-clinical and clinical information and is important for clinicians interested in the latest information about this class of drugs, for researchers and for students in the field.","brand":"WoB","offers":[{"title":"- \/ - \/ INTERNAL","offer_id":52336948248849,"sku":null,"price":0.0,"currency_code":"GBP","in_stock":true},{"title":"GB \/ NEW \/ INGRAM","offer_id":52336948805905,"sku":"NLS9783764369019","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764369019.jpg?v=1758165040"},{"product_id":"drug-treatment-of-sleep-disorders-book-antonio-guglietta-9783319115139","title":"Drug Treatment of Sleep Disorders","description":"Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52343069770001,"sku":"NLS9783319115139","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783319115139.jpg?v=1758173291"},{"product_id":"influenza-virus-sialidase-a-drug-discovery-target-book-mark-itzstein-9783034807791","title":"Influenza Virus Sialidase - A Drug Discovery Target","description":"Influenza continues to be an ongoing problem despite the existence of vaccines and drugs. Disease outbreaks can occur relatively quickly as witnessed with the recent emergence of the influenza virus A\/H1N1 pandemic. The development of new anti-influenza drugs is thus a major challenge.   This volume describes all aspects of the virus structure and function relevant to infection. The focus is on drug discovery of inhibitors to the enzyme sialidase, which plays a key role in the infectious lifecycle of the virus. Following an overview of the influenza virus, the haemagglutinin, the interactions with the cell receptors and the enzymology of virus sialidase, recent results in drug design are presented. These include a full coverage of the design, synthesis and evaluation of carbohydrate as well as non-carbohydrate influenza virus sialidase inhibitors. Further reviews of the clinical experience with influenza virus sialidase inhibitors and of the development of resistance to these inhibitor drugs complement the topic.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52405376712977,"sku":"NLS9783034807791","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783034807791.jpg?v=1758766807"},{"product_id":"recombinant-protein-drugs-book-p-buckel-9783764359041","title":"Recombinant Protein Drugs","description":"Recombinant protein drugs are intimately associated with the impressive  success story of the Biotech Industry during the past thirty years, some  of them belonging to the most successful pharmaceutical products. More  than thirty different proteins are available for a variety of clinical  applications, over 300 proteins are presently being evaluated in  clinical trials.  In this new volume of the MDT series, historical, technical and clinical  aspects of recombinant protein drug discovery and development are  presented, covering past, present and future highlights. Leading  scientists and co-founders of early Biotech companies describe technical  breakthroughs and the fascinating story of pioneering discoveries, as  well as the long way of translating them into products and business.  Therefore, this book represents an exciting documentation of the  beginning of a new era in the pharmaceutical industry. In addition,  scientists from basic research, clinic and industry actively involved in  new developments discuss...","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52406993813777,"sku":"NLS9783764359041","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764359041.jpg?v=1758771001"},{"product_id":"glucocorticoids-book-nicolas-j-goulding-9783764360597","title":"Glucocorticoids","description":"Following 50 years of glucocorticoid use in a clinical setting, an international body of expert scientists and physicians presents a survey of glucocorticoid pharmacology. This work traces the history of glucocorticoid biology from the seminal description of glucocorticoid insufficiency by Thomas Addison in the mid-19th century, up to advances in elucidating the molecular basis of glucocorticoid action. Important discoveries are presented, as well as milestones in drug development, a survey of current clinical practice, and prospects for novel glucocorticoid-based therapeutics. This work should be of special interest to workers in the fields of endocrinology, inflammation and autoimmune disease.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52408628085009,"sku":"NLS9783764360597","price":0.0,"currency_code":"GBP","in_stock":true},{"title":"US \/ NEW \/ INGRAM","offer_id":52762250936593,"sku":"NIN9783764360597","price":0.0,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764360597.jpg?v=1758774692"},{"product_id":"antidepressants-book-brian-e-leonard-9783764359331","title":"Antidepressants","description":"This work covers important clinical issues such as the outcome of long term treatment with antidepressants, the time of onset of the antidepressant response and the limitations of the antidepressants currently available.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52409032638737,"sku":"NLS9783764359331","price":0.0,"currency_code":"GBP","in_stock":true},{"title":"US \/ NEW \/ INGRAM","offer_id":52762249625873,"sku":"NIN9783764359331","price":0.0,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764359331.jpg?v=1758774723"},{"product_id":"hmg-coa-reductase-inhibitors-book-gerd-schmitz-9783764363079","title":"HMG-CoA Reductase Inhibitors","description":"HMG-CoA reductase inhibitors (statins) are established drugs for the  treatment of hypercholesterolemia. Furthermore, they induce regression  of vascular atherosclerosis as well as reduction of  cardiovascular-related morbidity and death in patients with and without  coronary artery disease. This book deals with statins which have  substantially altered the approach to therapy of atherosclerosis and its  sequelae. Emphasis is placed on the scientific background to the  discoveries and the development of the therapy, including an overview of  the current state of knowledge of the drugs. Clinical data are reviewed  extensively. This book not only provides the reader with valuable  information but also stimulates further research into the pathogenesis  of atherosclerosis and the  mechanisms behind the action of effective  statins. It sets the stage for creative thinking among scientists of  many disciplines for the accomplishment of our ultimate goals in  treating atherosclerosis and its sequelae. This topical volume...","brand":"WoB","offers":[{"title":"- \/ - \/ INTERNAL","offer_id":52410960675089,"sku":null,"price":0.0,"currency_code":"GBP","in_stock":true},{"title":"GB \/ NEW \/ INGRAM","offer_id":52410960838929,"sku":"NLS9783764363079","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764363079.jpg?v=1758780601"},{"product_id":"modern-immunosuppressives-book-h-j-schuurman-9783764359812","title":"Modern Immunosuppressives","description":"Expanding from the classic use of immunosuppressants in transplantation and rejection, this current overview highlights their new roles in clinical medicine. Immunosuppressants are at the forefront of new treatment modalities. Individual chapters focus on their use not only in prevention or treatment of transplant rejection, but also on their use in immune-complex and autoimmune diseases, including rheumatoid arthritis; on combination therapies to achieve synergy in immunosuppression; on new drugs, low molecular weight chemicals, the use of antibodies and gene therapy; on immunological tolerance to prevent or inhibit transplant rejection; and how data derived from transplant studies can be applied to other avenues of immunosuppression. Clinicians and researchers will appreciate the scope of the work and the presentation of new approaches in the rapidly developing field of immunosuppression.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52410998161681,"sku":"NLS9783764359812","price":0.0,"currency_code":"GBP","in_stock":true},{"title":"US \/ NEW \/ INGRAM","offer_id":53085228335377,"sku":"NIN9783764359812","price":0.0,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764359812.jpg?v=1758781270"},{"product_id":"bipolar-depression-molecular-neurobiology-clinical-diagnosis-and-pharmacotherapy-book-carlos-a-zarate-jr-9783319316871","title":"Bipolar Depression: Molecular Neurobiology, Clinical Diagnosis, and Pharmacotherapy","description":"This book brings together mental health professionals and researchers to offer the most up-to-date information on the diagnosis, treatment, and research surrounding bipolar depression. Its individual chapters provide valuable diagnostic information, allowing clinicians to distinguish between the various mood disorders. Further, they: review the course, outcome, and genetics of this highly heritable condition; offer a thorough overview of the neurobiology of the disorder, including what is known from neuroimaging work; delineate the treatment of bipolar depression in special populations such as children and pregnant women; address suicide, focusing on the need for assessment during both acute and maintenance treatment with interventions appropriate to a patient’s symptoms and history; and cover acute and long-term treatment strategies for bipolar depression, including both traditional and novel therapeutics for the disorder, as well as non-pharmacological treatments.  This second edition reflects significant advances, including an improved understanding of the altered neurobiology of patients suffering from bipolar depression, new information on pathophysiology and genetic findings drawn from diverse studies, and a discussion of the significant strides made towards improved treatment with already available and novel agents.","brand":"WoB","offers":[{"title":"- \/ - \/ INTERNAL","offer_id":52425360081169,"sku":null,"price":0.0,"currency_code":"GBP","in_stock":true},{"title":"GB \/ NEW \/ INGRAM","offer_id":52425360933137,"sku":"NLS9783319316871","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783319316871.jpg?v=1759154588"},{"product_id":"ace-inhibitors-book-g-plante-9783034875813","title":"ACE Inhibitors","description":"Angiotensin converting enzyme inhibitors (ACEI) represent the first class of antihypertensive agents that was designed and developed on the basis of a well-defined physiopathological axis of arterial hypertension, a vascular dis­ order that is now becoming one of the major causes of morbidity\/mortality, not only in developed societies but also in the highly populated developing coun­ tries [1]. CAPTOPRIL, the prototype of the \"PRIL\" family, which now comprises more than 40 molecule-species, was quite hazardous and the clinical develop­ ment almost failed when serious side-effects were reported in an alarmist fash­ ion in reputable scientific journals, such as the New England Journal of Medicine and Lancet. Squibb \u0026amp; Sons came very close to withdrawing CAPTOPRIL from clinical investigation [2]. However, after re-examination of the data obtained from different categories of patients and appropriate dose-adjustments, the clinical use of CAPTOPRIL turned out to be revolutionary. The prototype, as well as other members of the \"PRIL\" family became the starting point for numerous basic and clinical research programs, focusing on the interactions of ACEI with the kinin, endothelin, and nitric oxide systems, and the contribution of the receptors for AT I, AT 2, bradykinin Bland B , ETA and ET B to the pharmacological actions 2 of the respective peptides. This research activity led to the development of new pharmacological agents, such as the angiotensin receptor antagonists and, more recently, the neutral endopeptidase inhibitors. In the near future, bradykinin receptor antagonists also will be available to modulate ACEI phar­ macological actions.","brand":"WoB","offers":[{"title":"- \/ - \/ INTERNAL","offer_id":52426460627217,"sku":null,"price":0.0,"currency_code":"GBP","in_stock":true},{"title":"GB \/ NEW \/ INGRAM","offer_id":52426461282577,"sku":"NLS9783034875813","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783034875813.jpg?v=1759157885"},{"product_id":"valproate-book-wolfgang-lscher-9783034897617","title":"Valproate","description":"Since the fortuitous discovery of its anticonvulsant activIty in 1962, valproate has established itself worldwide as a major antiepileptic drug against several types of epileptic seizures. Clinical experience with valpro- ate has continued to grow in recent years, including use of valproate for diseases other than epilepsy, for example in bipolar disorders and migraine. In this volume on valproate emphasis is placed on the scientific back- ground leading to the discovery of val pro ate, its subsequent pharmacologi- cal and toxicological characterization, and its clinical development into one of the most widely and successfully used anti epileptic drugs, a real mile- stone in drug therapy. The current state of knowledge of valproate will be reviewed by experts in the field, including new hypotheses about its mecha- nisms of action, its metabolism into pharmacologically active metabolites, its unique distribution characteristics, its unwanted hepatotoxic and terato- genic adverse effects and its various clinical uses. Furthermore, the wide variety of available pharmaceutical formulations of valproate, including novel controlled-release formulations, will be outlined. The monograph is aimed at a broad readership, particularly neurologists, psychiatrists and basic scientists working in the field of epilepsy research. Because the monograph also deals with structure-activity relationships of valproate as well as of its metabolites and analogs, the book should also serve for rese- archers working in medicinal chemistry, particularly in the pharmaceutical industry.","brand":"WoB","offers":[{"title":"- \/ - \/ INTERNAL","offer_id":52426482024721,"sku":null,"price":0.0,"currency_code":"GBP","in_stock":true},{"title":"GB \/ NEW \/ INGRAM","offer_id":52426482614545,"sku":"NLS9783034897617","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783034897617.jpg?v=1759157955"},{"product_id":"hepatitis-prevention-and-treatment-book-joseph-m-colacino-9783034896177","title":"Hepatitis Prevention and Treatment","description":"Chronic viral hepatitis has emerged as one of the most common causes of disease and death worldwide. Because of their unique modes of replication and intimate association with the host immune system, hepatitis B virus (HBV) and hepatitis C virus (HCV) pose challenging problems to scientists in basic and applied research as well as to clinicians engaged in disease management. Although approved antiviral therapy is available for chronic HBV, the emergence of viral resistance provides a rationale for the development of novel chemotherapeutic agents. The lack of a robust cell culture system for HCV replication and a readily accessible small-animal model of HCV infection have hampered the development of antiviral agents for HCV. Neverthe-less, new antiviral agents targeting HCV are now in preclinical and clinical development.   This monograph, providing an up-to-date overview of the field of Hepatitis Prevention and Treatment, includes contributions from internationally recognized experts in the field of viral hepatitis, and covers the current state of knowledge and practice regarding the molecular biology, immunology, biochemistry, pharmacology and clinical aspects of chronic HBV and HCV infection. The volume includes salient topics such as: the history and epidemiology of HBV and HCV; recent insights into the molecular mechanisms of viral replication; the host immune response to infection and a discussion of the use (HBV) or potential development (HCV) of vaccines; the current standard of care for chronically-infected patients; and emerging therapies and issues associated with current antiviral treatments. The latest information to researchers and clinicians actively engaged in viral hepatitis research is provided, but also sufficient background and discussion of the literature to benefit the newcomer to the field.","brand":"WoB","offers":[{"title":"- \/ - \/ INTERNAL","offer_id":52426493886737,"sku":null,"price":0.0,"currency_code":"GBP","in_stock":true},{"title":"GB \/ NEW \/ INGRAM","offer_id":52426494542097,"sku":"NLS9783034896177","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783034896177.jpg?v=1759157996"},{"product_id":"anxiolytics-book-mike-briley-9783034895811","title":"Anxiolytics","description":"For over thirty years the benzodiazepines monopolised not only the anxiolytic market but also clinical and animal research in anxiety. Indeed many animal tests developed since the 1960s have been optimised for the benzodiazepines and some programmes have even screened candidates as potential anxiolytics on their benzodiazepine-like side-effects rather than their anxiolytic activity. With the realisation of the drawbacks of the benzodiazepines, namely their potential for tolerance and dependency, there has been a renewed interest in alternative anxiolytics both from existing drugs such as the tricyclic and monoamine oxidase antidepressants and from newer agents such as buspirone. In addition anxiety is no longer considered to be a unique entity but rather an umbrella term for a series of specific anxiety disorders such as panic disorder without or with agoraphobia, generalised anxiety disorder (GAD), specific phobias, social phobias and post-traumatic stress disorder (PTSD). These new clinical categories have opened another dimension in the therapy of anxiety requiring the optimisation of treatments for different syndromes. This book is a critical review of today's anxiolytics and those that may become the anxiolytics of tomorrow. What is clear is that currently there are few clinically satisfactory alternatives to the benzodiazepines for the treatment of acute anxiety. For chronic anxiety, it is generally agreed that benzodi- azepines are not the treatment of first choice. The tricyclic and monoamine oxidase antidepressants, the serotonin reuptake inhibitors and buspirone offer better solutions for chronic anxiety but they are still far from being ideal.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52426868850961,"sku":"NLS9783034895811","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783034895811.jpg?v=1759159223"},{"product_id":"sildenafil-book-udo-dunzendorfer-9783034896313","title":"Sildenafil","description":"This drug is a landmark discovery, which consequently has become the definitive therapy for the treatment of erectile dysfunction (ED). Following the major breakthrough in the field of nitric oxide (NO)-physiology and pharmacology leading to sildenafil being marketed, the most current information is presented in this reference book, including ongoing research from several disparate groups about NO as endothelium-derived relaxing factor (EDRF) and also as a neurotransmitter for nerves innervating erectile tissue in mammals.   The development of sildenafil as an oral phosphodiesterase-5 (PDE5) inhibitor drug for the treatment of ED resulted in one of the first products, which made its way successfully from basic NO research to routine clinical therapy.   This volume addresses all fields of sildenafil application in both men and women. In a highly competitive research environment with a critical medical need for drug improvements the reader will learn more about clinical resistance to sildenafil treatment and the modalities to overcome the failure rates.    The individual chapters cover clinical use, pharmacokinetics, pharmacodynamics, biochemistry, and cultural aspects. They are written by leading experts in their respective fields. Therefore, readers – whether professionals in the pharmaceutical industry, physicians treating ED, biochemists, chemists or pharmacologists – will find a detailed and up-to-date knowledge base about current research activities and an excellent overview for further research on this compound class and its cultural impact.","brand":"WoB","offers":[{"title":"- \/ - \/ INTERNAL","offer_id":52426987045137,"sku":null,"price":0.0,"currency_code":"GBP","in_stock":true},{"title":"GB \/ NEW \/ INGRAM","offer_id":52426987667729,"sku":"NLS9783034896313","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783034896313.jpg?v=1759159599"},{"product_id":"atypical-antipsychotics-book-bart-a-ellenbroek-9783034895712","title":"Atypical Antipsychotics","description":"The introduction of chlorpromazine in 1953, and haloperidol in 1958, into clinical practice dramatically altered the therapy of schizophrenic patients. Although representing by no means a cure for this severe psychiatric ill­ ness, it allowed, for the first time, to adequately control the severe hallu­ cinations and delusional beliefs which prevent these patients from leading a more or less independent life. Indeed these antipsychotics (and the many congeners that were to follow) significantly reduced the number ofchronic schizophrenic inpatients in psychiatric clinics all over the world. However soon after their introduction it became clear that, like all other available drugs, antipsychotics were by no means miracle drugs. In fact, two major problems appeared. First, the antipsychotics had very little effect on the so-called negative or defect symptoms, like social isolation, apathy and anhedonia, and secondly virtually all antipsychotics produced a number of side-effects, of which the neurological (often called extra­ pyramidal) side-effects were the most troublesome. Especially the tardive dyskinesia, which occurred in about 15 to 20% of the patients after pro­ longed treatment, represented a major problem in the treatment of schizo­ phrenic patients.","brand":"WoB","offers":[{"title":"- \/ - \/ INTERNAL","offer_id":52427733729553,"sku":null,"price":0.0,"currency_code":"GBP","in_stock":true},{"title":"GB \/ NEW \/ INGRAM","offer_id":52427734352145,"sku":"NLS9783034895712","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783034895712.jpg?v=1759161891"},{"product_id":"hmg-coa-reductase-inhibitors-book-gerd-schmitz-9783034894517","title":"HMG-CoA Reductase Inhibitors","description":"HMG-CoA reductase inhibitors (statins) are established drugs for the  treatment of hypercholesterolemia. Furthermore, they induce regression  of vascular atherosclerosis as well as reduction of  cardiovascular-related morbidity and death in patients with and without  coronary artery disease. This book deals with statins which have  substantially altered the approach to therapy of atherosclerosis and its  sequelae. Emphasis is placed on the scientific background to the  discoveries and the development of the therapy, including an overview of  the current state of knowledge of the drugs. Clinical data are reviewed  extensively. This book not only provides the reader with valuable  information but also stimulates further research into the pathogenesis  of atherosclerosis and the  mechanisms behind the action of effective  statins. It sets the stage for creative thinking among scientists of  many disciplines for the accomplishment of our ultimate goals in  treating atherosclerosis and its sequelae. This topical volume...","brand":"WoB","offers":[{"title":"- \/ - \/ INTERNAL","offer_id":52428577767697,"sku":null,"price":0.0,"currency_code":"GBP","in_stock":true},{"title":"GB \/ NEW \/ INGRAM","offer_id":52428578488593,"sku":"NLS9783034894517","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783034894517.jpg?v=1759164554"},{"product_id":"calcium-channel-blockers-book-thophile-godfraind-9783034895996","title":"Calcium Channel Blockers","description":"The drugs named calcium channel blockers (CCBs) were initially termed cal­ cium antagonists (see Chapter 1). They are also designated as calcium entry blockers (CEBs), calcium blockers, calcium channel antagonists, calcium channel inhibitors (and in French anticalciques). As this is reported in several chapters of this book, their main effect is a blockade of calcium entry into cells through voltage operated calcium channels (VOCCs). Chemically related drugs, such as Bay K 8644, exert the opposite effect by increasing the proba­ bility of calcium channel opening. One of the subcommittees of the Nomenclature Committee (NC-IUPAR) of the International Union of Pharmacology has been devoted to the classification of calcium channels and the site of action of drugs modifying channel function. The members of this Committee are noted for their significant contribution to the field (Tab. 1). A report has been published in 1992 in Pharmacological Reviews [3]. A list of criteria was approved for the identification of distinct drug binding 2 sites on Ca + channels. It included: (a) the demonstration of a stereoselective binding site supported by drug interaction studies (competition with other drugs, non-competitive interactions with other sites, reversal of inhibitory effects by channel activators); (b) demonstration of the electrophysiologieal effects of the drug and selectivity of action compared to other sites; (c) deter­ mination of the affinity for the type and subtype of ion channel. These criteria have identified different classes of Ca antagonists (see Chapter 2).","brand":"WoB","offers":[{"title":"- \/ - \/ INTERNAL","offer_id":52429377831185,"sku":null,"price":0.0,"currency_code":"GBP","in_stock":true},{"title":"GB \/ NEW \/ INGRAM","offer_id":52429378650385,"sku":"NLS9783034895996","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783034895996.jpg?v=1759166754"},{"product_id":"fluoroquinolone-antibiotics-book-allan-r-ronald-9783034894371","title":"Fluoroquinolone Antibiotics","description":"Since the introduction of ciprofloxacin in 1987, fluoroquinolones have expanded far beyond their early role in the treatment of urinary tract infections. Clinical applications beyond genitourinary tract infections include upper and lower respiratory infections, gastrointestinal infections, gynecologic infec- tions, sexually transmitted diseases, and some skin and soft tissue infections. Their ease of administration, favorable pharmacokinetic properties, excellent tolerability, and efficacy give them enormous potential for use and misuse alike. Quinolones have few common adverse effects, most notably nausea, headache and dizziness. Less frequent but more serious adverse events include prolongation of the corrected QT interval, phototoxicity, liver enzyme abnor- malities, arthropathy, and cartilage and tendon abnormalities. While possess- ing many of the favorable properties of intravenous agents, most fluoro- quinolones offer the convenience of oral administration, thus contributing to decreased health-care costs through increased outpatient therapy and short- ened hospital stays. With the recent introduction of agents such as gatifloxacin and moxifloxacin, the traditional Gram-negative coverage of fluoroquinolones has been expanded to include Gram-positive organisms, most importantly Streptococcus pneumoniae.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52429614448913,"sku":"NLS9783034894371","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783034894371.jpg?v=1759167408"},{"product_id":"drug-treatment-of-sleep-disorders-book-antonio-guglietta-9783319379203","title":"Drug Treatment of Sleep Disorders","description":"Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.","brand":"WoB","offers":[{"title":"- \/ - \/ INTERNAL","offer_id":52430822572305,"sku":null,"price":0.0,"currency_code":"GBP","in_stock":true},{"title":"GB \/ NEW \/ INGRAM","offer_id":52430823325969,"sku":"NLS9783319379203","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783319379203.jpg?v=1759170781"},{"product_id":"antidepressants-book-brian-e-leonard-9783034895262","title":"Antidepressants","description":"Important clinical issues as the outcome of long term treatment with  antidepressants, the time of onset of the antidepressant response and  the limitations of the antidepressants currently available are covered  in this monograph. Leading researchers in the area of clinical and  experimental psychopharmacology critically assess the progress in their  specialist fields. The mechanisms of action of antidepressants are  considered, followed by clinical research into the role of the  hypothalamic-pituitary-adrenal axis and the immune system in the biology  of depression and in response to treatment. The final chapter deals with  the important chemical entities now undergoing development as  antidepressants. The purpose of this monograph is not only to inform but  also to stimulate research into the biology of depression and the  mechanisms behind the action of effective antidepressants.  This monograph is of interest to psychiatrists, psychologists,  pharmacologists, neuroscientists and endocrinologists.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52430847443217,"sku":"NLS9783034895262","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783034895262.jpg?v=1759170846"},{"product_id":"methotrexate-book-bruce-n-cronstein-9783764359591","title":"Methotrexate","description":"This book provides multidisciplinary reviews of the mechanism of action and uses of methotrexate in the treatment of cancer, psoriasis, gynecologic and inflammatory diseases. The intended audience is composed of clinicians involved in the care of patients suffering from oncologic, gynecologic, rheumatic diseases as well as scientists involved in research into the pathogenesis and treatment of these diseases. This book is unique in that it provides a single, state-of-the-art source for information regarding the mechanism and use of methotrexate in many different areas of medicine.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52431302689041,"sku":"NLS9783764359591","price":0.0,"currency_code":"GBP","in_stock":true},{"title":"US \/ NEW \/ INGRAM","offer_id":52762249396497,"sku":"NIN9783764359591","price":0.0,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764359591.jpg?v=1759172117"},{"product_id":"tnf-alpha-inhibitors-book-jeffrey-m-weinberg-9783764372484","title":"TNF-alpha Inhibitors","description":"Over the last decade, the advent of biologic agents has greatly revolutionized therapeutic medicine in the management of chronic inflammatory diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis. Elucidation of the complex web of cytokine network and the roles of these cytokines in the pat- genesis of inflammatory disorders provided one of the key catalysts for the advancement of targeted biologic therapy in autoimmune and inflammatory diseases. TNF-? is known to play a crucial role in the pathogenesis of many chronic inflammatory diseases. Elevated levels of TNF-? have been demonstrated in Crohn's disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, sugge- ing a role for TNF-? in their pathogenesis. Although TNF-? plays a critical role in the activation of innate and acquired immune responses, the persistence of the immune response and inappropriate production of TNF-? can produce pathological changes resulting from chronic inflammation and tissue damage. The purpose of this volume is to provide a comprehensive overview of the development, pharmacology, efficacy, and safety of the currently available TNF-? inhibitors - etanercept, infliximab, and adalimumab. The initial three chapters of the volume provide a background on the field on TNF-? and its inhibition. Chapter 1 provides an introduction to TNF and reviews the pathophysiology of this cytokine. Chapter 2 then presents the h- tory of the development of TNF inhibitors. The pharmacology of these agents is reviewed in Chapter 3.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52432843145489,"sku":"NLS9783764372484","price":0.0,"currency_code":"GBP","in_stock":true},{"title":"US \/ NEW \/ INGRAM","offer_id":52762259390737,"sku":"NIN9783764372484","price":0.0,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764372484.jpg?v=1759176152"},{"product_id":"valproate-book-wolfgang-loscher-9783764358365","title":"Valproate","description":"In this book, emphasis is placed on the scientific background leading to the discovery of valproate, and its clinical development into one of the most widely used antiepileptic drugs, a milestone in drug therapy. It reviews the state of the drug, and looks at hypotheses on its mechanisms of action, its metabolism into pharmacologically active metabolites, its unique distribution characteristics, and its various clinical uses.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52433475404049,"sku":"NLS9783764358365","price":0.0,"currency_code":"GBP","in_stock":true},{"title":"US \/ NEW \/ INGRAM","offer_id":53085241344273,"sku":"NIN9783764358365","price":0.0,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764358365.jpg?v=1759178110"},{"product_id":"proton-pump-inhibitors-book-lars-olbe-9783764358976","title":"Proton Pump Inhibitors","description":"Inhibition of the proton pump in the parietal cells has been established as the main therapeutic principle in the treatment of acid-related diseases, such as peptic ulcer and gastro-oesophageal reflux. The proton pump inhi- bitors are tailored for their purpose. They accumulate in the target cell, are activated by acid and bind strongly to the specific target - the proton pump. The clinical superiority of the proton pump inhibitors is due not only to their high efficacy but also to the long duration of the acid inhibition in comparison with other antisecretory drugs. At present when drug discovery mostly relies on identification and characterization of potential targets by genome research, molecular biology, combinatorial chemistry and automated screening, it seems worthwhile to present the development of the tITst proton pump inhibitor - omeprazol- starting from a chemical structure with an observed antisecretory effect but also severe toxic effects that had to be eliminated. As always, basic and applied research operate luind in hand to optimize the delicate balance be- tween efficacy and safety of a new drug. This goal often involves time and many different specialists.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52434811453713,"sku":"NLS9783764358976","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764358976.jpg?v=1759181698"},{"product_id":"cannabinoids-as-therapeutics-book-raphael-mechoulam-9783764370558","title":"Cannabinoids as Therapeutics","description":"In recent years, cannabis research has concentrated on the potential of cannabinoids as therapeutic substances, particularly in serious chronic illnesses such as multiple sclerosis. Most volumes published on cannabinoids so far concentrate on the biological activity, biochemistry and pharmacology, whereas this volume concentrates on the diseases, the physiological effects and therapeutic use of cannabinoids. The volume editor Prof. Mechoulam was the first who isolated the prime active constituent (THC, Tetrahydrocannabiol) of marijuana. He published extensively on the pharmacological activities of cannabinoids. The volume is of interest to researchers and clinicians from pharmacology, neuroscience, and medicinal research.","brand":"WoB","offers":[{"title":"- \/ - \/ INTERNAL","offer_id":52480041713937,"sku":null,"price":0.0,"currency_code":"GBP","in_stock":true},{"title":"GB \/ NEW \/ INGRAM","offer_id":52480042729745,"sku":"NLS9783764370558","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783764370558.jpg?v=1759849639"},{"product_id":"bipolar-depression-molecular-neurobiology-clinical-diagnosis-and-pharmacotherapy-book-carlos-a-zarate-jr-9783319810966","title":"Bipolar Depression: Molecular Neurobiology, Clinical Diagnosis, and Pharmacotherapy","description":"This book brings together mental health professionals and researchers to offer the most up-to-date information on the diagnosis, treatment, and research surrounding bipolar depression. Its individual chapters provide valuable diagnostic information, allowing clinicians to distinguish between the various mood disorders. Further, they: review the course, outcome, and genetics of this highly heritable condition; offer a thorough overview of the neurobiology of the disorder, including what is known from neuroimaging work; delineate the treatment of bipolar depression in special populations such as children and pregnant women; address suicide, focusing on the need for assessment during both acute and maintenance treatment with interventions appropriate to a patient’s symptoms and history; and cover acute and long-term treatment strategies for bipolar depression, including both traditional and novel therapeutics for the disorder, as well as non-pharmacological treatments.  This second edition reflects significant advances, including an improved understanding of the altered neurobiology of patients suffering from bipolar depression, new information on pathophysiology and genetic findings drawn from diverse studies, and a discussion of the significant strides made towards improved treatment with already available and novel agents.","brand":"WoB","offers":[{"title":"- \/ - \/ INTERNAL","offer_id":52481393885457,"sku":null,"price":0.0,"currency_code":"GBP","in_stock":true},{"title":"GB \/ NEW \/ INGRAM","offer_id":52481394868497,"sku":"NLS9783319810966","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783319810966.jpg?v=1759851671"},{"product_id":"gene-therapy-for-autoimmune-and-inflammatory-diseases-book-yuti-chernajovsky-9783034601641","title":"Gene Therapy for Autoimmune and Inflammatory Diseases","description":"In this monograph about gene therapy of autoimmune and inflammatory d- orders we have gathered international experts and leaders from different fields to review the state of the art advances on topics ranging from disease entities to vectors and engineered cells. The different approaches described in each chapter take into consideration the biomedical knowledge of these diseases and address the complexities of delivering long-term genetic interventions. Gene therapy also serves as a testing ground for new therapeutic entities and helps provide proof of principle for their potential therapeutic role in animal models of disease. Scaling up from mice to men still remains an important h- dle not only from the quantitative point of view, but also for currently unknown and unexpected secondary effects of the vector or the transgene. Some of these approaches have already been tested in the clinic, but much more needs to be done to understand the human conditions treated and the n- ural history of their pathology. We are indebted to the secretarial assistance of Ms. Lin Wells (Bone and Joint Research Unit, London, UK) and the help of Hans Detlef Kluber for his help in getting this book published. We hope this book will be of interest to c- nicians and scientists and inspiring to students of the subject who will use their own ingenuity and knowledge to further forward this discipline into clinical use.","brand":"WoB","offers":[{"title":"- \/ - \/ INTERNAL","offer_id":52500735918353,"sku":null,"price":0.0,"currency_code":"GBP","in_stock":true},{"title":"GB \/ NEW \/ GARDNERS","offer_id":52500736737553,"sku":"NGR9783034601641","price":0.0,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783034601641.jpg?v=1760138783"},{"product_id":"next-generation-antibody-drug-conjugates-adcs-and-immunotoxins-book-ulf-grawunder-9783319836096","title":"Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins","description":"This book describes the newest developments in antibody drug conjugates and immunotoxins, paving their way to clinical application. Lessons learned from the current state of the art are used to further improve our understanding of their mechanisms of action and off target activities.     The book introduces scientists to all of the prerequisites that must be properly addressed, including identification of the right target, specific traits of target binding antibodies, proper selection of the toxic payload, internalization induced by binding, and next generation conjugation and linker technologies. These knowledge-based, revolutionary new drug principles will form the cornerstone of the future standard of care and will lead to major advances in application, as well as improved quality of life and patient survival rates. This book will be of interest to biotech companies and researchers working in the fields of immunology, pharmacology, and oncology.","brand":"WoB","offers":[{"title":"GB \/ NEW \/ INGRAM","offer_id":52600008605969,"sku":"NLS9783319836096","price":0.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0784\/4072\/6801\/files\/9783319836096.jpg?v=1761087822"}],"url":"https:\/\/www.worldofbooks.com\/en-gb\/collections\/milestones-in-drug-therapy-book-series.oembed?page=2","provider":"World of Books ","version":"1.0","type":"link"}